AACR Cancer Progress Report 2026 Highlights AI, Liquid Biopsy and Vaccines

AACR Releases Its 16th Annual Cancer Progress Report

The American Association for Cancer Research (AACR) has published the 16th edition of its Cancer Progress Report, an annual review that combines current data on cancer incidence, mortality and survivorship with an assessment of how research is changing patient care. The 2026 report arrives at a moment when cancer science is moving quickly across several fronts at once, from basic laboratory discovery to translational studies and clinical trials, and from population-level prevention to the support of people living after a diagnosis.

Unlike a narrow study focused on a single experiment or treatment, the AACR report functions as a broad status update. It describes the landscape of cancer in the United States and explains how work supported by federal agencies—principally the National Institutes of Health (NIH), the National Cancer Institute (NCI), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC)—contributes to better health and longer lives. The document is also an advocacy tool, closing with policy recommendations and a call for Congress and other policymakers to protect the research investments and merit-based systems that underpin progress.

What the Report Examines

The report is organized around the full arc of cancer research and care. It highlights the latest advances in understanding cancer, preventing it, detecting it earlier and treating it, while also addressing the practical needs of patients and survivors. That range reflects a central premise of modern oncology: progress is rarely the product of one breakthrough alone. It emerges from years of basic science, careful translation into human studies, rigorous clinical testing and the population science that helps researchers understand who is affected and why.

Among the areas covered in the 2026 edition are:

• Current data on cancer incidence, mortality and survivorship.
• Advances in understanding the biology of cancer.
• Strategies for prevention and earlier detection.
• New and emerging treatment approaches.
• Information relevant to supporting patients and survivors.
• Forward-looking technologies and therapeutics, including artificial intelligence, liquid biopsy, cancer vaccines and RNA medicines.
• Policy recommendations aimed at sustaining progress for all Americans.

By bringing these threads together, the report offers a view of where cancer research stands and where it may be heading.

Federal Investment as a Foundation

A recurring theme is the role of public investment in research. The AACR report links much of the progress it describes to support from the NIH, NCI, FDA and CDC. These agencies fund and facilitate basic, translational and clinical research, help evaluate new treatments and diagnostics, and support public health efforts that can reduce the burden of cancer.

The report's policy section argues that protecting this funding is not an abstract budget question. Research pipelines depend on stable, predictable support, and clinical advances often take years to move from an initial discovery to a therapy that can be offered to patients. Interruptions or cuts can slow that process, particularly for early-career scientists and for studies that are difficult to fund through other means. The AACR's call to action urges lawmakers to preserve investments in research and to maintain merit-based review systems that direct resources toward the most promising science.

Advances Across the Cancer Continuum

The report's scope makes clear that progress against cancer is not limited to a single stage of the disease. Improvements in prevention and detection can reduce the number of people who develop advanced cancer, while better treatments can extend and improve lives for those who do. Survivorship research and support services address what happens after treatment, including the long-term health and quality-of-life needs of people who have lived through cancer.

Understanding, Preventing and Detecting Cancer

Basic research continues to deepen knowledge of cancer's complexity, revealing vulnerabilities that can be targeted by new interventions. Translational research helps turn those insights into tools that can be tested in people. Population science, meanwhile, examines patterns of disease and the factors that influence risk, screening and access to care. Together, these areas inform efforts to prevent cancer where possible and to find it earlier when prevention is not enough.

Treating Cancer and Supporting Survivors

Clinical research remains the bridge between laboratory promise and patient benefit. The AACR report describes how advances in treatment are being tested and, in some cases, incorporated into care. It also emphasizes that supporting patients and survivors is an essential part of the cancer research enterprise, not a separate concern. The report includes information about the needs of people living with and beyond cancer, underscoring that the goal of research is not only longer survival but better health across the entire experience.

Looking Ahead: AI, Liquid Biopsy, Cancer Vaccines and RNA Medicines

The 2026 report devotes attention to technologies that could shape the next phase of cancer care. Artificial intelligence is one of the most closely watched areas, with potential applications across research and clinical decision-making. Liquid biopsy, an approach that relies on analyzing biological samples such as blood rather than requiring a traditional tissue biopsy, is another field highlighted for its promise in detection and monitoring.

The report also points to cutting-edge therapeutics, including cancer vaccines and RNA medicines. These approaches represent a broadening of the therapeutic toolkit beyond conventional treatments, and they reflect the growing ability of scientists to design interventions with specific biological targets in mind. The report frames these developments as promising, while placing them within the larger context of research that must still be validated and translated into routine care.

Patient Stories Put Progress in Human Terms

Numbers and technical descriptions can only convey so much. To illustrate the real-world impact of cancer research, the report includes personal stories from patients who have benefited from recent scientific breakthroughs. Their accounts serve as a reminder that behind every data point is a person, a family and a community affected by cancer. By sharing these experiences, the AACR connects the science of cancer to the lives it is meant to improve.

A Researcher's Perspective

AACR President Keith Flaherty, MD, FAACR, who chairs the AACR Cancer Progress Report 2026 Steering Committee, offered a long-view assessment of the field. He described a remarkable transformation over his 25-year career as a physician-scientist, pointing to advances in genomics, immunology and artificial intelligence that have provided deeper insight into the complexities of cancer. That knowledge, he said, is helping researchers develop highly effective treatments and entirely new therapeutic approaches that can more precisely match each patient's disease.

His comments capture the report's overall tone: optimism grounded in evidence, paired with an awareness that continued progress depends on sustained commitment to research.

Why the Report Matters

The AACR Cancer Progress Report serves multiple audiences. For researchers, it is a synthesis of a fast-moving field. For clinicians and patients, it offers a readable overview of advances that may eventually affect care. For policymakers, it is a case for why federal research investments matter and how they translate into health gains.

As the 16th edition makes clear, cancer research is not a single effort but a continuum that stretches from laboratories to clinics to communities. The report's combination of data, patient stories and policy recommendations reflects that reality. Its message is that progress is possible—and that maintaining the systems that produce it is a choice that requires attention and support.

This article is based on reporting by Medical Xpress. Read the original article.